



ACADIA Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

August 23, 2016

SAN DIEGO--(BUSINESS WIRE)--Aug. 23, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the underwriters for the Company's previously announced public offering have fully exercised their option to purchase an additional 909,090 shares. All 6,969,696 shares sold in the offering were offered by ACADIA at a price to the public of \$33.00 per share, for total gross proceeds to ACADIA of approximately \$230.0 million before deducting underwriting discounts and commissions and other offering expenses payable by ACADIA. The closing of the sale of 6,060,606 shares was completed on August 15, 2016, and the closing of the sale of 909,090 shares pursuant to the full exercise by the underwriters of their option to purchase additional shares was completed earlier today.

J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynch acted as the joint book-running managers for the offering. Cowen and Company, LLC, Piper Jaffray & Co. and Needham & Company, LLC acted as co-managers for the offering.

The shares of common stock described above were offered by ACADIA pursuant to a shelf registration statement filed by ACADIA with the Securities and Exchange Commission (SEC) that became automatically effective on March 3, 2014. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website located at <http://www.sec.gov>. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email to: prospectus-eq-fi@jpmchase.com, or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email to: prospectus-ny@ny.email.gs.com, or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email to: dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160823006265/en/>

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

Lisa Barthelemy, Senior Director, Investor Relations
(858) 558-2871